Exclusion Criteria:~* History of active peptic ulcer disease within 1 year of screening.~* Clinically
significant cardiac arrhythmia.~* Resting pulse less than 50.~* Active neoplastic (cancer) disease (skin tumors
other than melanoma are not excluded; participants with stable prostate cancer may be included at the
discretion of the Project Director).~* Use of another investigational agent within 2 months of screening.~*
History of clinically significant stroke.~* Current evidence or history in the past 2 years of epilepsy, focal
brain lesion, head injury with loss of consciousness and/or immediate confusion after the injury, or DSM-IV
criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or
substance abuse.~* Blindness, deafness, language difficulties or any other disability which may prevent the
participant from participating or cooperating in the protocol.~* Residence in a skilled nursing facility; but
patients in an assisted living facility are acceptable.~Excluded Medications:~* Use of cholinesterase
inhibitors (galantamine, rivastigmine, donepezil, and tacrine) within 2 months of screening.~* Regular use of
narcotic analgesics (>2 doses per week) within 4 weeks of screening.~* Use of medications with significant
central nervous system anticholinergic activity within 2 months of screening (e.g. tricyclic antidepressants,
diphenhydramine).~* Use of anti-Parkinsonian medications (including Sinemet, amantadine, bromocriptine,
pergolide, selegiline) within 2 months of screening.~* Participation in any other investigational drug study
within 2 months of screening (individuals may not participate in any other drug study while participating in
this protocol).~* Use of estrogen is allowed if the dose has been stable for 3 months prior to screening.~* Use
of vitamin E is allowed if the dose has been stable for 3 months prior to screening.~* Use of memantine is
allowed if the dose has been stable for 3 months prior to screening.
